GlassScriptPhysician profile
William C Williams
NPI 1093814949
$4,579.88
in general payments reported to CMS, 2019-2025
30 companies · $849 in 2025
The $849 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,377 · 2022: $528 · 2023: $872 · 2024: $954 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.25 |
| Education | $119.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,276.36 | 2021-2025 | |
| Novo Nordisk INC | $596.64 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $491.47 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $486.28 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Merck Sharp & Dohme LLC | $352.91 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $208.93 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $129.21 | 2022-2023 | Xarelto |
| Corcept Therapeutics | $125.86 | 2025 | Korlym |
| Astellas Pharma US INC | $114.66 | 2024-2025 | Veozah |
| Pfizer INC. | $112.76 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.87 | 2021-2025 | Jardiance |
| Mayne Pharma Commercial LLC | $64.16 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.08 | 2023-2025 | |
| Esperion Therapeutics, INC. | $61.74 | 2021-2022 | |
| Abbott Laboratories | $54.75 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $38.19 | 2023-2024 | Vyepti |
| Sumitomo Pharma America, INC. | $32.59 | 2023-2024 | Gemtesa |
| Nevro Corp. | $32.04 | 2024 | Senza |
| Kowa Pharmaceuticals America, INC. | $30.25 | 2021-2024 | Livalo |
| Exact Sciences Corporation | $29.40 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $27.27 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.13 | 2021 | |
| Nestle Healthcare Nutrition INC. | $22.98 | 2021 | |
| Next Science LLC | $21.40 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.02 | 2021 | |
| Axsome Therapeutics, INC. | $19.55 | 2025 | Symbravo |
| Mylan Specialty L.P. | $16.17 | 2021 | |
| Glaxosmithkline, LLC. | $14.75 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.51 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.